Literature DB >> 26319229

Evaluation of antimicrobial susceptibility of Escherichia coli strains isolated in Rabat University Hospital (Morocco).

Nabil Alem1,2,3, Mohammed Frikh4,5, Abdellatif Srifi6, Adil Maleb7, Mariama Chadli8,9, Yassine Sekhsokh10,11, Lhoucin Louzi12, Azzedine Ibrahimi13, Abdelhay Lemnouer14,15, Mostafa Elouennass16,17.   

Abstract

BACKGROUND: Escherichia coli (E. coli) is the most commonly isolated bacteria in human pathology. In Morocco the data concerning the nature and the rates of antibiotic resistance of E. coli in both hospitals and city environment remains relatively poor and needs further investigations.
METHODS: During a 16 months period, E. coli isolates were collected from different culture specimens received in the Bacteriology Department of the Military teaching Hospital Mohammed-V-Rabat for routine diagnostic purposes. E. coli isolates were identified and their antimicrobial susceptibility pattern was determined.
RESULTS: A total of 1369 E. coli isolates comprising 33% (1369/4110) of culture-positive samples were consecutively collected. Isolates of E. coli were, in 40.5% (554/1369) of cases from hospitalized patients and in 59.5% (815/1369) of cases from outpatients. Urine isolates represented 82% (1123/1369) of the cases. High rates of resistance were found for amoxicillin (42.5%), cefalotin (30.4%), norfoloxacin (29.9%) and sulfamethoxazole (37.7%). The detection rate of ESBL was 6.1% (85/1369). In hospitalized patients 11.9% of the isolates of E. coli (66/554) had an ESBL phenotype while in outpatients cases only 2.3% of isolates of E. coli (19/815) had this phenotype.
CONCLUSIONS: Our findings suggest that more judicious use of antibiotics is needed especially in probabilistic treatment. The emergence of ESBL in the Moroccan cities is an indicator of the severity of this problem that is not limited to health care facilities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26319229      PMCID: PMC4553218          DOI: 10.1186/s13104-015-1380-9

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Background

Escherichia coli (E. coli) is a common commensal of the intestine of humans and animals but can also be found in water, soil and vegetation [1]. It is the most frequently isolated bacteria from clinical samples [1], indeed E. coli is the pathogen most involved in urinary tract infections [2-4] and one of the common agents responsible for ear infections, sepsis and wound infections [5, 6]. In the developing countries, E. coli represents the agent most commonly responsible for food and waterborne diarrhea and causes high mortality in children under 5 years old [7]. Escherichia coli dominates the overall spectrum of the bacterial infections in both hospitals and the community [8]. Therefore its susceptibility to antibiotics reflects both the hospital and community antibiotic selection pressure [9]. The emergence of resistance is a global phenomenon, although the rates of antibiotic resistance remain different between developed and developing countries [10, 11]. This emergence complicates the management of infections and impacts the use of widely prescribed antibiotics in clinical practice such as penicillins, sulfonamides and fluoroquinolones. The aim of this study is to determine the resistance rate of E. coli isolates to different antibiotics in the Rabat Military Teaching Hospital Mohammed V and to compare these rates of resistance between hospitalized patients and outpatients and between urine isolates and other isolates.

Methods

Materials

The present study was conducted in the bacteriology department of the Rabat Military Teaching Hospital Mohammed V. Retrospectively from April 1, 2012 to July 31, 2013. We included all E. coli isolates received from hospitalized patients and outpatients. We highlight that under Moroccan law no ethical approval is required for a retrospective study based on laboratory data and no consent from patients is necessary to carry out further tests on samples collected for other purposes. In order to eliminate duplicates, only one strain isolated from the same patient with the same antibiotic susceptibility was included.

Bacterial identification and antimicrobial susceptibility

The identification of bacterial isolates was based on cultural, morphological and biochemical characteristics. Biochemical identification was set up using API20E (bio-Mérieux SA, Marcy-l’Étoile/France). Antibiotic susceptibility was determined using the agar diffusion method (Mueller–Hinton medium) and its interpretation was made according to the recommendations of antibiogram committee of the French Society for Microbiology [12]. Antibiotics tested were: amoxicillin–clavulanic acid, cephalothin, cefoxitin, ceftriaxone, ertapenem, gentamicin, amikacin, norfoloxacin, cotrimoxazole and fosfomycin. Detection of extended β-lactamases (ESBL) was performed by phenotypic method based on the detection of synergy between amoxicillin–clavulanic acid disc and three discs of third-generation cephalosporins: cefotaxim, ceftazidime and cefepime [12].

Statistical analysis

The Chi square test was used to compare resistance rates. The difference between the frequencies was considered to be significant when p was <0.05.

Results

During the period of our study, were received at the bacteriology department a total of 32,522 samples. The sex ratio male/female was 1.03 (16,515/16,007). The rate of urine samples was 25.09 % (8159/32,522) with a sex ratio male/female 0.73 (3459/4700). The overall incidence of isolation of E. coli was 33.3 % (1369/4110). The sex ratio male/female was 0.65 (538/830). Isolates of E. coli were in 40.5 % (554/1369) of cases from hospitalized patients and in 59.5 % (815/1369) of cases from outpatients. Urine isolates represented 82 % (1123/1369) of the cases. Isolates with ESBL phenotype represented 6.1 % of all E. coli isolates (85/1369). In hospitalized patients 11.9 % of the isolates of E. coli (66/554) had an ESBL phenotype while in outpatients cases only 2.3 % of isolates of E. coli (19/815) had this phenotype. Furthermore 84.4 % (43/66) of the isolates with ESBL phenotype in hospitalized patients were also resistant to fluoroquinolones (FQ resistance + ESBL). High rates of resistance were found for amoxicillin–clavulanic acid (42, 5 %), cefalotin (30, 4 %), norfoloxacin (29, 9 %) and cotrimoxazole (37, 7 %). Table 1 shows the rates of resistance (R + I) within E. coli isolates depending on the nature of patients. Frequencies of resistance among isolates from hospitalized patients were higher than those from outpatients in the case of: amoxicillin–clavulanic acid (p < 0.001), cephalothin (p < 0.001), cefoxitin (p = 0.001), ceftriaxone (p < 0.001), amikacin (p = 0.001) and norfoloxacin (p = 0.003).
Table 1

Rates of resistance (R + I) of Escherichia coli isolates depending on the nature of patients

Isolates n Out patients (R + I)Hospitalized patients (R + I) p
n % n %
Amoxicillin/clavulanic ac (AMC)126328638.024648.1<0.001
Cefalotin (KF)126319626.118536.2<0.001
Cefoxitin (FOX)1256222.9346.70.001
Ceftriaxone (CRO)1032284.0329.8<0.001
Ertapenem (ERT)1251141.9173.40.098
Gentamicin (GEN)1137669.86313.60.044
Amikacin (AK)125040.5142.80.001
Norfoloxacine (NOR)102018226.111335.10.003
Cotrimoxazole (SXT)124426135.219538.80.203
Fosfomycin (FOS)1082132.092.10.974
Rates of resistance (R + I) of Escherichia coli isolates depending on the nature of patients Table 2 shows the rates of resistance (R + I) of E. coli isolates depending on the nature of sample. Frequencies of resistance among isolates from urine samples were lower than those from others samples in the case of: amoxicillin–clavulanic acid (p < 0.001), cephalothin (p < 0.001), cefoxitin (p = 0.004), ceftriaxone (p < 0.001), gentamicin (p < 0.001) and amikacin (p < 0.001).
Table 2

Rates of resistance (R + I) of Escherichia coli isolates depending on the nature of samples

Urine (R + I)Other samples (R + I) p
n % n %
Amoxicillin/clavulanic ac (AMC)42238.813556.7<0.001
Cefalotin (KF)29226.910343.1<0.001
Cefoxitin (FOX)403.7198.00.004
Ceftriaxone (CRO)605.65021.3<0.001
Ertapenem (ERT)262.441.70.516
Gentamicin (GEN)909.23817.7<0.001
Amikacin (AK)70.7104.2<0.001
Norfoloxacine (NOR)31329.17431.20.52
Cotrimoxazole (SXT)39837.29238.80.648
Fosfomycin (FOS)181.942.10.779
Rates of resistance (R + I) of Escherichia coli isolates depending on the nature of samples The rate of simultaneous resistance to all of the three antibiotics which are most used orally (AMC + SXT + FQ) was 8.3 % in isolates from hospitalized patients compared to 9.9 % outpatients (p = 0.34).

Discussion

In our study E. coli represented over a third of the total isolates of our department. Urinary tract remains the main site of colonization-infection totaling about 82 % of all isolates. These proportions are similar to those found in French and European epidemiological studies [13, 14]. We recorded important levels of resistance (R + I) for amoxicillin–clavulanic acid (38 % in outpatients and 48.1 % in hospitalized patients) these percentages of resistance are comparable to those of Onerba-France—with 36 % in city and 45 % in hospital [15]. Rates of resistance (R + I) for AMC in hospitalized patients were higher than those from outpatients (p < 0.001). ESBL and resistance to fluoroquinolones are the two most worrying phenomena [16]. A review of Moroccan data shows varying levels of frequency of ESBL by region, structures and the size of the populations studied. These rates vary between 7 and 15 % [17, 18]. Our study showed a 12.4 % rate of ESBL E. coli in hospitalized patients, this rate remains similar to that recorded by a recent study in Rabat [17] and lower than the one recorded in Khartoum-Soudan [8]. ESBL is not limited to health care facilities; international studies show that in community setting rates of ESBL E. coli range from 1.3 to 4.8 % [19-21]. We recorded a 2.5 % rate of ESBL E. coli in our outpatients. Fluoroquinolone resistance is associated with the misuse of these molecules in human and veterinary medicine [22]. This resistance varies from one geographic area to another with 10 % in France and United States vs. 40 % in China [15, 23, 24]. Our study found a rate of resistance of E. coli to fluoroquinolones 29.9 % which is similar to that recorded in Rabat [17] with a frequency of resistance among isolates from hospitalized patients higher than those from outpatients (p = 0.003). A frequent association between genetic determinants of Qnr and those of ESBL was reported by several studies [25]. In our study we found 43 multiresistant strains (ESBL + FQ resistance), more genetic studies are needed to characterize the nature of fluoroquinolone resistance determinants carried by these strains. The rate of resistance to aminoglycosides remains relatively low (gentamicin 11.1 %, amikacin 1.3 %) as reported in the literature [8]. Amikacin appears to be the most effective molecule of this class of antibiotics explained by the fact that it is strictly used in hospitals and is rarely used in the first line therapy. In our study, fosfomycin remains largely active on isolates of E. coli with low resistance rates especially among urine isolates (1.9 %). These results suggest that we should favor the use of fosfomycin as a molecule for the empirical treatment of community urinary infections.

Conclusion

Periodic monitoring of antibiotic resistance in different bacterial isolates has become essential given the constant evolution of the bacterial ecology and the emergence of antibiotic resistance. The high rate of multiresistance shown in this study should encourage us to be more judicious in the use of antibiotics especially in probabilistic treatment. Indeed the 10 % threshold of resistance is substantially exceeded for several antibiotics used in our hospital. The emergence of ESBL in the community is an indicator of the seriousness of this problem which appears not to be limited to health care facilities.
  22 in total

1.  Antimicrobial susceptibility patterns of community-acquired uropathogens in Tehran, Iran.

Authors:  Nasim Kashef; Gholamreza Esmaeeli Djavid; Sahba Shahbazi
Journal:  J Infect Dev Ctries       Date:  2010-05-01       Impact factor: 0.968

2.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

Authors:  Melinda M Neuhauser; Robert A Weinstein; Robert Rydman; Larry H Danziger; George Karam; John P Quinn
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

3.  Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals.

Authors:  Amani El Kholy; Hadia Baseem; Geraldine S Hall; Gary W Procop; David L Longworth
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

4.  [Susceptibility to antibiotics of Escherichia coli isolated from community-acquired urinary tract infections].

Authors:  R Fabre; A Mérens; F Lefebvre; G Epifanoff; F Cerutti; H Pupin; D Tardif; J-D Cavallo; I Ternois
Journal:  Med Mal Infect       Date:  2010-04-22       Impact factor: 2.152

5.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Authors:  Douglas J Biedenbach; Gary J Moet; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

6.  [Resistance to fluoroquinolones and third generation cephalosporin of Escherichia coli isolated from urines].

Authors:  M R Tagajdid; L Boumhil; M Iken; M Adnaoui; A Benouda
Journal:  Med Mal Infect       Date:  2008-12-06       Impact factor: 2.152

7.  Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.

Authors:  Jesús Rodríguez-Baño; Juan Alcalá; Jose Miguel Cisneros; Fabio Grill; Antonio Oliver; Juan Pablo Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2009-02-17       Impact factor: 5.790

8.  [Qnr-type quinolone resistance in extended-spectrum beta-lactamase producing enterobacteria in Abidjan, Ivory Coast].

Authors:  N Guessennd; S Bremont; V Gbonon; A Kacou-Ndouba; E Ekaza; T Lambert; M Dosso; P Courvalin
Journal:  Pathol Biol (Paris)       Date:  2008-10-15

Review 9.  [Rational antibiotic therapy of urinary tract infections].

Authors:  Florian M E Wagenlehner; Kurt G Naber; Wolfgang Weidner
Journal:  Med Monatsschr Pharm       Date:  2008-10

10.  Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006.

Authors:  David C Bean; Daniel Krahe; David W Wareham
Journal:  Ann Clin Microbiol Antimicrob       Date:  2008-06-18       Impact factor: 3.944

View more
  3 in total

1.  Update on the resistance of Escherichia coli isolated from urine specimens in a Moroccan hospital: a review of a 7-year period.

Authors:  Elmostafa Benaissa; Nadia Elmrimar; Elmehdi Belouad; Youness Mechal; Mohammed Ghazouani; Fatna Bsaibiss; Yassine Benlahlou; Mariama Chadli; Nadia Touil; Abdelhay Lemnaouer; Adil Maleb; Mostafa Elouennass
Journal:  Germs       Date:  2021-06-02

2.  Bacteriological profile of urinary tract infections and antibiotic susceptibility of Escherichia coli in Algeria.

Authors:  Nouara Ait-Mimoune; Houda Hassaine; Meriem Boulanoir
Journal:  Iran J Microbiol       Date:  2022-04

Review 3.  Antimicrobial resistance among GLASS pathogens in Morocco: an epidemiological scoping review.

Authors:  Chakib Nejjari; Youness El Achhab; Amina Benaouda; Chakib Abdelfattah
Journal:  BMC Infect Dis       Date:  2022-05-07       Impact factor: 3.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.